Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

被引：0
|
作者：
Antonio Daponte
Simona Signoriello
Luigi Maiorino
Bruno Massidda
Ester Simeone
Antonio Maria Grimaldi
Corrado Caracò
Giuseppe Palmieri
Antonio Cossu
Gerardo Botti
Antonella Petrillo
Secondo Lastoria
Ernesta Cavalcanti
Pasquale Aprea
Nicola Mozzillo
Ciro Gallo
Giuseppe Comella
Paolo Antonio Ascierto
机构：
[1] Istituto Nazionale Tumori Fondazione Pascale,Department of Melanoma
[2] Second University,Medical Statistics
[3] S.Gennaro Hospital Napoli,Medical Oncology
[4] University of Cagliari,Medical Oncology
[5] Institute of Biomolecular Chemistry,Unit of Cancer Genetics
[6] C.N.R.,Department of Pathology
[7] Azienda Ospedaliero Universitaria,Department of Pathology
[8] Istituto Nazionale Tumori Fondazione Pascale,Department of Radiology
[9] Istituto Nazionale Tumori Fondazione Pascale,Department of Nuclear Medicine
[10] Istituto Nazionale Tumori Fondazione Pascale,Laboratory Medicine Unit
[11] Istituto Nazionale Tumori Fondazione Pascale,Vascular Access Unit
[12] Istituto Nazionale Tumori Fondazione Pascale,undefined
[13] the Southern Italy Cooperative Oncology Group (SICOG),undefined
来源：
Journal of Translational Medicine | / 11卷
关键词：
Melanoma; Fotemustine; Dacarbazine; Interferon-α;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma:: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    Hauschild, A
    Garbe, C
    Stolz, W
    Ellwanger, U
    Seiter, S
    Dummer, R
    Ugurel, S
    Sebastian, G
    Nashan, D
    Linse, R
    Achtelik, W
    Mohr, P
    Kaufmann, R
    Fey, M
    Ulrich, J
    Tilgen, W
    BRITISH JOURNAL OF CANCER, 2001, 84 (08) : 1036 - 1042
  • [42] Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    A Hauschild
    C Garbe
    W Stolz
    U Ellwanger
    S Seiter
    R Dummer
    S Ugurel
    G Sebastian
    D Nashan
    R Linse
    W Achtelik
    P Mohr
    R Kaufmann
    M Fey
    J Ulrich
    W Tilgen
    British Journal of Cancer, 2001, 84 : 1036 - 1042
  • [43] COMBINATION CHEMOTHERAPY OF DACARBAZINE AND FOTEMUSTINE IN DISSEMINATED MALIGNANT-MELANOMA - EXPERIENCE OF THE FRENCH STUDY-GROUP
    AVRIL, MF
    BONNETERRE, J
    DELAUNAY, M
    GROSSHANS, E
    FUMOLEAU, P
    ISRAEL, L
    BUGAT, R
    NAMER, M
    CUPISSOL, D
    KERBRAT, P
    MONTCUQUET, P
    ARCAUTE, V
    BIZZARI, JP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (02) : 81 - 84
  • [44] Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma
    Rasi, G
    Terzoli, E
    Izzo, F
    Pierimarchi, P
    Ranuzzi, M
    Sinibaldi-Vallebona, P
    Tuthill, C
    Garaci, E
    MELANOMA RESEARCH, 2000, 10 (02) : 189 - 192
  • [45] Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
    Jiang, Guan
    Li, Rong-Hua
    Sun, Chao
    Liu, Yan-Qun
    Zheng, Jun-Nian
    PLOS ONE, 2014, 9 (12):
  • [46] DACARBAZINE, VINDESINE, AND CISPLATIN COMBINATION CHEMOTHERAPY IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY
    GUNDERSEN, S
    CANCER TREATMENT REPORTS, 1987, 71 (11): : 997 - 999
  • [47] Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
    Bedikian, A. Y.
    DeConti, R. C.
    Conry, R.
    Agarwala, S.
    Papadopoulos, N.
    Kim, K. B.
    Ernstoff, M.
    ANNALS OF ONCOLOGY, 2011, 22 (04) : 787 - 793
  • [48] A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
    Hersh, Evan M.
    O'Day, Steven J.
    Powderly, John
    Khan, Khuda D.
    Pavlick, Anna C.
    Cranmer, Lee D.
    Samlowski, Wolfram E.
    Nichol, Geoffrey M.
    Yellin, Michael J.
    Weber, Jeffrey S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 489 - 498
  • [49] A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.
    Marshall, Ernest
    Coupland, Sarah
    Corrie, Philippa
    Damato, Bertil
    Danson, Sarah
    Dobson, Lisa
    Evans, T. R. Jeffry
    Goodman, Andrew
    Kalirai, Helen
    Jones, Sarah
    Kumar, Satish
    Larkin, James M. G.
    Lorigan, Paul
    Nicholson, Steve
    Ottensmeier, Christian
    Silcocks, Paul
    Steven, Neil
    Tudur-Smith, Catrin
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
    Demetri, George D.
    Schoffski, Patrick
    Grignani, Giovanni
    Blay, Jean-Yves
    Maki, Robert G.
    Van Tine, Brian A.
    Alcindor, Thierry
    Jones, Robin L.
    D'Adamo, David R.
    Guo, Matthew
    Chawla, Sant
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) : 3433 - +
12345